Management of Distal Esophageal Adenocarcinoma

Initial Evaluation and Staging

A complete staging workup should include endoscopic ultrasound (EUS) to determine the T and N stage accurately, as this will guide treatment decisions, according to the Journal of Clinical Oncology 1, 2
Comprehensive CT of chest/abdomen/pelvis is recommended to evaluate for distant metastases and regional lymphadenopathy, as suggested by the Annals of Oncology 3
PET/CT has already been performed showing localized disease, which is consistent with potentially resectable disease, as noted in the Journal of Clinical Oncology 1, 2
Nutritional assessment and optimization prior to initiating therapy is crucial, as emphasized by the Annals of Oncology 3

The American Society of Clinical Oncology recommends multimodality therapy, including either preoperative chemoradiotherapy or perioperative chemotherapy followed by surgery, for patients with newly diagnosed distal esophageal adenocarcinoma (cT2-T3) without evidence of metastatic disease and good functional status 1, 2
Preoperative chemoradiotherapy, using weekly carboplatin and paclitaxel with concurrent radiation, is a preferred option for bulkier tumors with proximal extension, as suggested by the Journal of Clinical Oncology 4, 3
Perioperative chemotherapy, using the FLOT regimen, is preferred for smaller tumors at the gastroesophageal junction, as recommended by the Journal of Clinical Oncology 4, 6
Transthoracic esophagectomy with en bloc two-field lymphadenectomy is the recommended surgical approach for distal esophageal tumors, according to the Journal of Clinical Oncology 4, 7

Adjuvant nivolumab should be administered if the patient received preoperative chemoradiotherapy and has residual disease in the resection specimen, as suggested by the Annals of Oncology 3
Completion of the remaining postoperative cycles of chemotherapy is essential if the patient received perioperative chemotherapy, as emphasized by the Journal of Clinical Oncology 4, 6
Regular surveillance with imaging and endoscopy is crucial for monitoring disease recurrence, as recommended by the Annals of Oncology 3

Factors favoring preoperative chemoradiotherapy include larger tumor size, more proximal extension, and concern for achieving complete surgical resection, as noted by the Journal of Clinical Oncology 4, 8
Factors favoring perioperative chemotherapy include smaller tumor size, higher likelihood of complete surgical resection, and patient inability to tolerate radiation therapy, as suggested by the Journal of Clinical Oncology 4, 8

Patients should proceed to surgery even after complete clinical response to preoperative therapy, as data for a watch-and-wait strategy are limited in esophageal adenocarcinoma, as emphasized by the Annals of Oncology 3
Definitive chemoradiotherapy is recommended for patients who cannot tolerate surgery, as suggested by the Journal of Clinical Oncology 4, 3
The quality and extent of surgery significantly impact outcomes, with adequate lymphadenectomy and clear margins being critical factors, as noted by the Journal of Clinical Oncology 4, 6